What Is Semaglutide? Definition and What Research Reports
Semaglutide is a long-acting synthetic analogue of the gut hormone GLP-1 (glucagon-like peptide-1). It is a modified 31-amino-acid peptide engineered to resist enzymatic breakdown and bind albumin, giving it a roughly weekly dosing interval. It is a prescription pharmaceutical approved in several regions for type 2 diabetes and chronic weight management. Published trials and reviews have reported weight reduction, glycaemic effects, and a predominantly gastrointestinal adverse-event profile. This page defines the term and summarises the literature; it is not medical advice.
Plain definition
Semaglutide is a laboratory-made version of a hormone the human gut releases after eating, called GLP-1 (glucagon-like peptide-1). Natural GLP-1 tells the pancreas to release insulin when blood sugar rises and signals the brain that the body has eaten. The natural hormone is destroyed within minutes; semaglutide was chemically altered so it survives far longer in the bloodstream, which is why it is described in the literature as a long-acting GLP-1 receptor agonist. It is a prescription medicine, not a supplement, and it is studied mainly in the contexts of type 2 diabetes and obesity. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medical condition or treatment.
The term in biochemical language
Semaglutide is a peptide analogue of human GLP-1 with approximately 94% sequence homology to the native hormone. Three structural changes distinguish it from GLP-1: substitution of alanine at position 8 with alpha-aminoisobutyric acid to block degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), a lysine substitution at position 34, and attachment of a C-18 diacid fatty-acid chain via a spacer at position 26 that promotes reversible binding to serum albumin. A review of the discovery programme that produced both liraglutide and semaglutide described this acylation strategy as the central design principle behind extending the circulating half-life of GLP-1 analogues (PMID 31031702). A systematic review of the clinical pharmacokinetics of semaglutide summarised absorption, distribution and elimination characteristics across subcutaneous and oral formulations, including the role of albumin binding in its prolonged exposure profile (PMID 38952487).
Mechanism as described in the literature
Semaglutide acts at the GLP-1 receptor, a G-protein-coupled receptor expressed in pancreatic islets, the gastrointestinal tract, and multiple brain regions. Preclinical work in rodents reported that semaglutide lowered body weight through distributed neural pathways rather than a single hypothalamic site, with the authors describing action across several central nervous system regions involved in appetite regulation (PMID 32213703). Reviews of obesity pharmacotherapy have described the clinical consequences of that receptor activity as reduced appetite, altered food preference and slowed gastric emptying (PMID 34942372).
Regulatory meaning of the term
In regulatory usage, "semaglutide" refers to a specific approved active pharmaceutical ingredient, and the brand names attached to it denote distinct approved indications and formulations. A review of Wegovy described the semaglutide product authorised for chronic weight management in adults meeting defined body-mass-index criteria, alongside the separate diabetes indication for the same molecule (PMID 34706925). Because these are approved prescription products in the United States, European Union and other jurisdictions, semaglutide is not a "research chemical" in the regulatory sense, even though material sold online is sometimes labelled "for research use only". That labelling describes a supplier's regulatory posture and does not indicate identity, purity or potency of the contents.
Where the term gets misused
- "Semaglutide peptide" as a wellness category. Semaglutide is a peptide by chemistry, but grouping it with unapproved research peptides obscures the fact that it is an approved drug with defined labelling and pharmacovigilance.
- "GLP-1" used interchangeably with semaglutide. GLP-1 is the endogenous hormone; semaglutide is one of several engineered analogues. Liraglutide, described alongside semaglutide in the discovery literature, is a different molecule with a different dosing interval (PMID 31031702).
- Confusion with tirzepatide. Tirzepatide is a dual GIP/GLP-1 receptor agonist and a distinct compound; a 2025 JAMA analysis examined semaglutide and tirzepatide separately in patients with heart failure with preserved ejection fraction (PMID 40886075).
- "Generic semaglutide". Reference to a generic version implies an approval pathway that the published literature summarised here does not describe.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeRelated terms
| Term | Relationship to semaglutide |
|---|---|
| GLP-1 | The endogenous incretin hormone semaglutide was modelled on |
| GLP-1 receptor agonist | The drug class semaglutide belongs to |
| Liraglutide | An earlier acylated GLP-1 analogue from the same discovery programme (PMID 31031702) |
| Tirzepatide | A separate dual-agonist molecule compared with semaglutide in some studies (PMID 40886075) |
| DPP-4 | The enzyme that degrades native GLP-1; semaglutide was engineered to resist it |
| Incretin | The physiological category of gut hormones including GLP-1 |
What the published literature reports
Body weight
A systematic review and meta-analysis of semaglutide for weight loss in people with obesity without diabetes pooled randomised trials and reported greater reductions in body weight with semaglutide than with placebo, while noting gastrointestinal adverse events as the most frequent tolerability issue (PMID 36578889). A 2024 analysis of long-term weight-loss outcomes in the SELECT trial examined participants with obesity and cardiovascular disease but without diabetes, and researchers reported that weight reduction was sustained over an extended follow-up period rather than fully reversing on continued treatment (PMID 38740993). A narrative review of semaglutide for overweight and obesity summarised the trial programme and described the magnitude of weight change as larger than that reported for earlier pharmacological options (PMID 36254579).
Cardiometabolic and other endpoints
Reviews positioned semaglutide within cardiovascular medicine, discussing weight reduction alongside metabolic risk-factor changes in populations with obesity (PMID 34942372). A 2025 JAMA study examined semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction, a population in which incretin therapies had previously received limited study (PMID 40886075).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appAdverse Events: What Studies Report
A dedicated safety review of semaglutide summarised adverse events observed across the clinical development programme and reported gastrointestinal effects — nausea, vomiting, diarrhoea and constipation — as the most commonly recorded, generally described as dose-related and most prominent during dose escalation (PMID 34305810). The same review discussed monitoring considerations including pancreatitis, gallbladder events, diabetic retinopathy and thyroid C-cell findings from rodent studies (PMID 34305810). The meta-analysis in obesity without diabetes similarly reported higher rates of gastrointestinal adverse events with semaglutide than placebo (PMID 36578889).
Case-level literature has described less common presentations. A 2024 report in Clinical Kidney Journal discussed semaglutide-associated kidney injury, with the authors framing dehydration from severe gastrointestinal symptoms as a plausible contributing mechanism (PMID 39258261). A separate 2024 case report described semaglutide-induced hyperemesis gravidarum, documenting severe vomiting in pregnancy in a patient exposed to semaglutide (PMID 38249445). Single case reports describe individual patients and do not establish population-level frequency.
How to read the term precisely
- Specify the formulation. Subcutaneous and oral semaglutide differ in absorption and exposure, as summarised in the pharmacokinetics review (PMID 38952487).
- Specify the population. Trials in type 2 diabetes, in obesity without diabetes, and in heart failure with preserved ejection fraction are not interchangeable evidence bases (PMID 38740993, PMID 40886075).
- Separate approved products from unlabelled material. The approved-product literature describes a defined ingredient with regulatory oversight (PMID 34706925); material of unknown provenance has no such characterisation.
This glossary entry defines a term and summarises what published studies reported. It does not describe how any compound should be used, and it is not a substitute for evaluation by a licensed clinician.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
- Semaglutide lowers body weight in rodents via distributed neural pathways (JCI Insight, 2020)
- Safety of Semaglutide (Frontiers in Endocrinology, 2021)
- Wegovy (semaglutide): a new weight loss drug for chronic weight management (Journal of Investigative Medicine, 2022)
- Semaglutide for the treatment of obesity (Trends in Cardiovascular Medicine, 2023)
- Semaglutide for the treatment of overweight and obesity: A review (Diabetes, Obesity & Metabolism, 2023)
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
- Semaglutide-induced Hyperemesis Gravidarum (JCEM Case Reports, 2024)
- Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (Nature Medicine, 2024)
- Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Design, Development and Therapy, 2024)
- Semaglutide-associated kidney injury (Clinical Kidney Journal, 2024)
- Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (JAMA, 2025)
Frequently asked questions
What does the word semaglutide actually mean?▾
Semaglutide names a specific synthetic analogue of the gut hormone GLP-1. The molecule was engineered with amino-acid substitutions and a fatty-acid chain that binds albumin, extending how long it circulates. A review of the discovery programme behind liraglutide and semaglutide described this acylation approach as the core design strategy for long-acting GLP-1 analogues (PMID 31031702).
Is semaglutide a peptide or a drug?▾
Both descriptions apply. Chemically it is a modified peptide; in regulatory terms it is an approved prescription pharmaceutical. A review of Wegovy described the semaglutide product authorised for chronic weight management in adults, separate from the same molecule's diabetes indication (PMID 34706925). Grouping it with unapproved research peptides misrepresents its regulatory status.
What does the research report about semaglutide and body weight?▾
A systematic review and meta-analysis in obesity without diabetes reported greater weight reduction with semaglutide than placebo across randomised trials (PMID 36578889). A 2024 analysis of the SELECT trial reported that weight loss was sustained over long-term follow-up in participants with obesity and cardiovascular disease but without diabetes (PMID 38740993).
What adverse events do studies report for semaglutide?▾
A dedicated safety review reported gastrointestinal effects — nausea, vomiting, diarrhoea and constipation — as the most common, typically dose-related and most prominent during escalation, and discussed pancreatitis, gallbladder, retinopathy and rodent thyroid C-cell findings as monitoring topics (PMID 34305810). Case literature has described semaglutide-associated kidney injury (PMID 39258261) and hyperemesis gravidarum (PMID 38249445).
How is semaglutide different from tirzepatide?▾
They are distinct molecules. Semaglutide acts at the GLP-1 receptor, while tirzepatide is a dual GIP/GLP-1 receptor agonist. A 2025 JAMA study examined semaglutide and tirzepatide as separate agents in patients with heart failure with preserved ejection fraction (PMID 40886075). Using the names interchangeably is a common terminology error.
How does semaglutide reduce appetite according to preclinical work?▾
A rodent study reported that semaglutide lowered body weight through distributed neural pathways, with the authors describing activity across multiple central nervous system regions involved in appetite rather than a single hypothalamic target (PMID 32213703). Reviews have summarised the clinical correlates as reduced appetite, altered food preference and slowed gastric emptying (PMID 34942372).
Do oral and injectable semaglutide behave the same way?▾
No. A systematic review of semaglutide's clinical pharmacokinetics summarised absorption, distribution and elimination across subcutaneous and oral formulations and described differences in exposure, with albumin binding underpinning the prolonged half-life in both cases (PMID 38952487). When reading studies, the formulation and population should be identified before comparing results.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.